Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
Dec. 31, 2021
Employee Benefit Plans
Employee Benefit Plans	12. Employee Benefit Plans The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the year ended December 31, 2021. As a result of the 401(k) plan compliance review for the year ended December 31, 2020, the Company contributed $25,905 to eligible participants during the third quarter of 2021. As of December 31, 2021, the Company has accrued an additional estimate of $20,334 for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December 31, 2021.

Employee Benefit Plans

12 Months Ended

Dec. 31, 2021

12. Employee Benefit Plans

The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the year ended December 31, 2021.

As a result of the 401(k) plan compliance review for the year ended December 31, 2020, the Company contributed $25,905 to eligible participants during the third quarter of 2021. As of December 31, 2021, the Company has accrued an additional estimate of $20,334 for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December 31, 2021.